The Peptide Field. DSIP: approval and evidence record.

Editorial review: 2026-08-30. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/dsip

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=dsip#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: No FDA-approved U.S. product; the July 2026 advisory vote did not add DSIP to the 503A list

Exact product limits: DSIP is also called emideltide. FDA separates emideltide free base from emideltide acetate, a salt form. These forms are not automatically the same as each other or as a product sold online. A product name does not prove its identity, contents, quality, or match to study material.

Human outcomes: Limited. Small older human studies gave DSIP mainly through a vein and reported mixed sleep results. The studies do not establish a treatment benefit.

Body effects in people: Unclear. Some studies measured short-term sleep or hormone changes after use through a vein. They do not define how DSIP acts in every person or product.

What the evidence shows: Small sleep studies from 1981 through 1992 tested DSIP, mostly through a vein. Some reported short sleep changes. Other controlled studies found little or no useful sleep benefit. One study measured a short-term change in a blood hormone, not better sleep. A few small studies also looked at narcolepsy or withdrawal symptoms.

What remains unknown: These studies do not prove that DSIP improves sleep, treats insomnia, or treats opioid or alcohol withdrawal. The studies were small and used different designs. They do not show long-term benefit or safety. FDA's 2026 review found no adequate evidence for the proposed under-the-skin route and no long-term effectiveness data. It also found no adequate safety or toxicity record for the proposed use.

Safety limits: FDA identified important limits in the human safety and product-quality record. Free base, acetate, and online products may differ. This guide gives no dosing, administration, sourcing, product-selection, or treatment instructions.

Approval claim: “DSIP is FDA-approved in the United States.”
Verdict: Misleading. FDA's briefing did not identify an FDA-approved U.S. drug containing emideltide. The current U.S. 503A list also does not list DSIP or emideltide. A substance record or a foreign or online product is not U.S. drug approval.
Evidence basis: Regulatory or product record. Scope: United States approval and 503A status as reviewed August 30, 2026.
Claim sources: https://www.fda.gov/media/193344/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23

Approval claim: “The 2026 advisory vote added DSIP to the 503A list or approved it.”
Verdict: Misleading. The July 2026 committee vote was advisory. It did not itself change the 503A list or approve a drug. The current U.S. list does not show DSIP or emideltide, and no final FDA approval was identified in this review.
Evidence basis: Regulatory or product record. Scope: The July 2026 advisory vote and United States 503A status as reviewed August 30, 2026; an advisory recommendation is not a final FDA decision or drug approval.
Claim sources: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193344/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. FDA Global Substance Registration System record for emideltide (DSIP). 2026. Accessed 2026-08-30. https://precision.fda.gov/uniisearch/srs/unii/YN28Z5YZ73

U.S. Food and Drug Administration. FDA evaluation of emideltide (DSIP) and related bulk drug substances. 2026. Accessed 2026-08-30. https://www.fda.gov/media/193344/download

U.S. Food and Drug Administration. July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting. 2026. Accessed 2026-08-30. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

Electronic Code of Federal Regulations. 21 CFR 216.23 bulk drug substances list. 2026. Accessed 2026-08-30. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23

PubMed. DSIP amino-acid sequence, synthesis, and activity. 1978. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/568769/

PubMed. Acute and delayed effects of DSIP on human sleep behavior. 1981. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/6895513/

PubMed. Synthetic DSIP and disturbed human sleep. 1981. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/7028502/

PubMed. Synthetic DSIP and sleep in people with insomnia. 1981. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/6112579/

PubMed. DSIP and 24-hour sleep-wake behavior in severe chronic insomnia. 1987. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/3622582/

PubMed. DSIP efficacy study in chronic insomnia. 1987. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/3583493/

PubMed. Double-blind DSIP study in chronic insomnia. 1992. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/1299794/

PubMed. DSIP and narcolepsy. 1984. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/6548968/

PubMed. DSIP in withdrawal syndromes from alcohol and opiates. 1984. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/6548969/

PubMed. Opioid detoxification with DSIP: open clinical trial. 1998. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/9617990/

PubMed. Intravenous DSIP and a blood hormone change in people. 1989. Accessed 2026-08-30. https://pubmed.ncbi.nlm.nih.gov/2554357/

Keep the limits, review date, and sources with this record. Check the current source for changes.